Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Thromboembolic and cardiovascular events after CAR-T cell therapy in multiple myeloma: A propensity-matched real-world analysis

Moath Albliwi, Firas Anaya, Rahaf Yaghi et al. Nov 03, 2025 pp. 2249-2249 10.1182/blood-2025-2249

Abstract Background Chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes in relapsed/refractory multiple myeloma (MM) b...

Dark genome interrogation identifies novel antigens in Acute Myeloid Leukemia – developing an off-the-shelf vaccine from machine learning to clinic

Rasmus Villebro, Benjamin Wolthers, Rasmus Andersen et al. Nov 03, 2025 pp. 278-278 10.1182/blood-2025-278

Abstract Introduction Durable responses remain rare in patients with Acute Myeloid Leukemia (AML) who are ineligible for intensive chemother...

Ruxolitinib and interferon alfa induce superior rates of complete peripheral blood count remission compared to anagrelide in hydroxyurea-exposed essential thrombocythemia

Tripura Vithala, Seungyeon Lee, Haley Roberts et al. Nov 03, 2025 pp. 3824-3824 10.1182/blood-2025-3824

Abstract Introduction: Essential thrombocythemia is a myeloproliferative neoplasm characterized by elevated platelets and a predilection for...

Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism, including by cancer site: Post-hoc analysis of the API-CAT randomised trial

Isabelle Mahé, Céline Chapelle, Philippe Girard et al. Nov 03, 2025 pp. 1343-1343 10.1182/blood-2025-1343

Abstract Background : As shown by the API-CAT study, extended anticoagulation with reduced-dose apixaban is non-inferior to full-dose apixab...

Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL)

Lucas Mix, Wichard Vogel, Britta Besemer et al. Nov 03, 2025 pp. 6001-6001 10.1182/blood-2025-6001

Abstract Background and Significance For many patients with AML and higher risk MDS, allogeneic hematopoietic stem cell translplantation (HS...

Funcional cure in advanced follicular lymphoma: Real word experience from two academic centers from Argentina

Sofía Rivarola, Nancy Cristaldo, Maria Orlova et al. Nov 03, 2025 pp. 1836-1836 10.1182/blood-2025-1836

Abstract Introduction: Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma. In most cases, it presents as asymp...

Empowering families through conversational design: A chatbot for sickle cell care

Tulika Banerjee, Morgan Greenleaf, Santiago Arconada Alvarez et al. Nov 03, 2025 pp. 2591-2591 10.1182/blood-2025-2591

Abstract Background Children's Healthcare of Atlanta (CHOA) provides care for over 2000 pediatric sickle cell disease (SCD) patients annuall...

High mortality rate of warm autoimmune haemolytic anaemia: Real-world incidence and outcomes from a comprehensive regional audit

Jun Yen Ng, Ry Cambourne, Meidelynn Ooi et al. Nov 03, 2025 pp. 4659-4659 10.1182/blood-2025-4659

Abstract Background: Warm autoimmune haemolytic anaemia (wAIHA) is rare but associated with significant mortality, morbidity, and treatment-...

Myeloid sarcoma as a pancreatic cancer mimic: Refining the clinical differential of pancreatic masses

Kevin Li, Philip Coffin, Raymond Wadlow et al. Nov 03, 2025 pp. 6942-6942 10.1182/blood-2025-6942

Abstract Introduction Myeloid sarcoma (MS) is a rare extramedullary tumor composed of immature granulocytes or monocytes and is an uncommon...

A quality improvement project to optimize VTE prophylaxis in surgical patients

Aimn W Abdujawad, Abdulrahman Al Raizah, Abdullah S. Al Saleh et al. Nov 03, 2025 pp. 2617-2617 10.1182/blood-2025-2617

Abstract Introduction Venous thromboembolism (VTE) is a leading cause of preventable morbidity and mortality among hospitalized surgical pat...

Efficacy of mitapivat in patients with transfusion-dependent alpha-thalassemia: Subgroup analysis from the ENERGIZE-T trial

Ashutosh Lal, Andreas Glenthøj, Hanny Al-Samkari et al. Nov 03, 2025 pp. 4699-4699 10.1182/blood-2025-4699

Abstract Introduction: Thalassemia is caused by an imbalance of globin chains within red blood cells (RBCs) creating an excess of α-globins...

Filter coagulation related risk factors associated with continuous renal replacement therapy in critically ill patients with hematologic disorders: A retrospective cohort study

Jiajing Wang, Jian Zhang, Xiaoying Wang et al. Nov 03, 2025 pp. 7902-7902 10.1182/blood-2025-7902

Abstract Background: For hematological critical illness with acute kidney injury, citrate anticoagulation and Continuous Venous-venous Hemod...

Semantic features associated with outcome in patients treated with CAR-T therapy

Jung Choi, Michael Jain, Frederick Locke et al. Nov 03, 2025 pp. 7077-7077 10.1182/blood-2025-7077

Abstract BACKGROUND: Recent development in chimeric antigen receptor (CAR) T-cell therapy has shown tremendous promise in providing a durabl...

Time to transfer – the clock is ticking: A quality improvement project

Tara Rakiewicz, Liam Heneghan, Brianna Costello et al. Nov 03, 2025 pp. 1082-1082 10.1182/blood-2025-1082

Abstract Background: Aggressive hematologic malignancies such as acute myeloid leukemia and aggressive lymphomas can be challenging to diagn...

Survival and response rates of histone deacetylase inhibitors in peripheral T-cell lymphoma: A comprehensive systematic review and meta-analysis of 67 studies.

Mahnoor Sukaina, Chandra Kakarala, Haritha Gandicheruvu et al. Nov 03, 2025 pp. 7170-7170 10.1182/blood-2025-7170

Abstract Introduction: Peripheral T-cell lymphomas (PTCL) account for 5-15% of non-Hodgkin lymphomas. It has high relapses and unfavorable p...

Racial and ethnic disparities in the risk of second primary malignancies among diffuse large B-cell lymphoma survivors in the United States

Pragati Advani, Han Yu, Kayla Catalfamo et al. Nov 03, 2025 pp. 6260-6260 10.1182/blood-2025-6260

Abstract Background: Previous studies have shown an increased risk of second primary malignancies (SPMs) among diffuse large B-cell lymphoma...

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Louis Williams, Taha Iftikhar, Sandra Mazzoni et al. Nov 03, 2025 pp. 3970-3970 10.1182/blood-2025-3970

Abstract Introduction The monoclonal gammopathies of renal significance (MGRS) are defined by the presence of a nephrotoxic monoclonal protei...

Survival disparities by race and income among adolescents and young adults with acute lymphoblastic leukemia

Salih Akgun, Muhammed Calik, Fatma Yilmaz et al. Nov 03, 2025 pp. 6336-6336 10.1182/blood-2025-6336

Abstract Background: Since 2012, the adoption of pediatric-inspired regimens, the integration of tyrosine kinase inhibit...

Characterizing return-to-school after pain-related hospitalizations and hospital re-admission risk in pediatric sickle cell disease

Megan Connolly, Sydney Forman, Sara Ropeta et al. Nov 03, 2025 pp. 4451-4451 10.1182/blood-2025-4451

Abstract Introduction: Pain is the primary cause of inpatient admissions in sickle cell disease (SCD), and re-admission to the hospital foll...

METTL14 overexpression identifies a biologically aggressive subgroup and correlates with adverse clinical outcomes in multiple myeloma

Liping Zuo, ZhiXin Li, Qun Li et al. Nov 03, 2025 pp. 5774-5774 10.1182/blood-2025-5774

Abstract Background N⁶-methyladenosine (m⁶A) is the most prevalent internal modification of eukaryotic mRNA and plays a central role in post...

Cardiac complete response in AL amyloidosis: Phenotypic characteristics, functional recovery, and survival outcomes of 63 patients

Eli Muchtar, Susan Geyer, Angela Dispenzieri et al. Nov 03, 2025 pp. 3960-3960 10.1182/blood-2025-3960

Abstract Cardiac involvement in AL amyloidosis significantly impacts both short and long-term survival. Achieving cardiac complete response...

Evolution of t(11;14) biology in multiple myeloma and it's role on outcomes to venetoclax treatment

Praneeth Reddy Sudalagunta, Filip Ionescu, Rafael Renatino Canevarolo et al. Nov 03, 2025 pp. 5730-5730 10.1182/blood-2025-5730

Abstract Introduction: The chromosomal translocation t(11;14)(q13;q32) is found in nearly 20% of multiple myeloma (MM) patients. MIDAS trial...

Automated AI classification in clinical flow cytometry: Transforming B-cell lymphoma diagnostics

Chrysanthi Tsamadou, Sven Maschek, Lisa Erdl et al. Nov 03, 2025 pp. 6122-6122 10.1182/blood-2025-6122

Abstract Introduction: Flow cytometry (FC) holds a pivotal role in hematological diagnostics. Although capable of turn-a...

TCR-T cells expressing a TCR recognizing the MPO propeptide-derived MPO132-140:HLA-a*02:01 specifically kill AML and spare healthy myeloid cells

Yibin Chen, Yanqing Huang, Xizeng Mao et al. Nov 03, 2025 pp. 2362-2362 10.1182/blood-2025-2362

Abstract Patients with AML/MDS have limited therapeutic options. While antigen-specific T cell therapies (e.g. CAR-T) have shown curative po...

Exploiting HLA-e restricted T cell receptors to develop universal cellular therapies for virus-associated malignancies

Chelston Ang, Simon Ellington, Allison Fry et al. Nov 03, 2025 pp. 5911-5911 10.1182/blood-2025-5911

Abstract Adoptive T cell receptor-engineered therapies (TCR-Ts) enable targeted redirection of T cells to tumor antigens presented by human...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page